Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis

References

• Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016 Jul;280(1):24–38. doi: 10.1111/joim.12444
   PubMed Web of Science ®Google Scholar
• Pachman LM, Khojah AM. Advances in juvenile dermatomyositis: myositis specific antibodies aid in understanding disease heterogeneity. J Pediatr. 2018 Apr;195:16–27. doi: 10.1016/j.jpeds.2017.12.053
   PubMed Web of Science ®Google Scholar
• Papadopoulou C, Chew C, Wilkinson MGL, et al. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023 Jun;19(6):343–362.
   PubMed Web of Science ®Google Scholar
• McCann LJ, Livermore P, Wilkinson MGL, et al. Juvenile dermatomyositis. Where are we now? Clin Exp Rheumatol. 2022 Feb;40(2):394–403.
   PubMed Web of Science ®Google Scholar
• Kim H, Huber AM, Kim S. Updates on juvenile dermatomyositis from the Last Decade: classification to outcomes. Rheum Dis Clin North Am. 2021 Nov;47(4):669–690. doi: 10.1016/j.rdc.2021.07.003
   PubMed Web of Science ®Google Scholar
• Tansley SL, Simou S, Shaddick G, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun. 2017 Nov;84:55–64.
   PubMed Web of Science ®Google Scholar
• Pachman LM, Nolan BE, DeRanieri D, et al. Juvenile dermatomyositis: new clues to diagnosis and therapy. Curr Treatm Opt Rheumatol. 2021 Mar;7(1):39–62.
   PubMedGoogle Scholar
• Wienke J, Deakin CT, Wedderburn LR, et al. Systemic and tissue inflammation in juvenile dermatomyositis: from pathogenesis to the quest for monitoring tools. Front Immunol. 2018;9:2951. doi: 10.3389/fimmu.2018.02951
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis & Rheumatism. 2013;65(2):314–324. doi: 10.1002/art.37754
   PubMed Web of Science ®Google Scholar
• Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial. Lancet. 2016;387(10019):671–678. doi: 10.1016/S0140-6736(15)01021-1
   PubMed Web of Science ®Google Scholar
• Wu JQ, Lu MP, Reed AM. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. World J Pediatr. 2020 Feb;16(1):31–43. doi: 10.1007/s12519-019-00313-8
   PubMed Web of Science ®Google Scholar
• Papadopoulou C, Wedderburn LR. Treatment of Juvenile Dermatomyositis: An Update. Paediatr Drugs. 2017 Oct;19(5):423–434. doi: 10.1007/s40272-017-0240-6
   PubMed Web of Science ®Google Scholar
• Ll Wilkinson MG, Deakin CT, Papadopoulou C, et al. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatr Rheumatol Online J. 2021 Sep 25;19(1):146. doi: 10.1186/s12969-021-00637-8
   PubMed Web of Science ®Google Scholar
• Kim H. Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy. Curr Opin Rheumatol. 2021 Sep 1;33(5):371–377. doi: 10.1097/BOR.0000000000000816
   PubMed Web of Science ®Google Scholar
• Paik JJ, Lubin G, Gromatzky A, et al. Use of janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol. 2023 Mar;41(2):348–358.
   PubMed Web of Science ®Google Scholar
• Huang B, Wang X, Niu Y, et al. Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis. Rheumatology (Oxford). 2023 Mar 1;62(3):1227–1237. doi: 10.1093/rheumatology/keac399
   PubMed Web of Science ®Google Scholar
• Olazagasti JM, Niewold TB, Reed AM. Immunological biomarkers in dermatomyositis. Curr Rheumatol Rep. 2015 Nov;17(11):68. doi: 10.1007/s11926-015-0543-y
   PubMed Web of Science ®Google Scholar
• Rodero MP, Decalf J, Bondet V, et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med. 2017 May 1;214(5):1547–1555. doi: 10.1084/jem.20161451
   PubMed Web of Science ®Google Scholar
• Wienke J, Bellutti Enders F, Lim J, et al. Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation. Arthritis & rheumat. 2019 Aug;71(8):1377–1390.
   PubMed Web of Science ®Google Scholar
• Turnier JL, Pachman LM, Lowe L, et al. Comparison of lesional juvenile myositis and lupus skin reveals overlapping yet unique disease pathophysiology. Arthritis & Rheumat. 2021 Jun;73(6):1062–1072.
   PubMed Web of Science ®Google Scholar
• Moneta GM, Pires Marafon D, Marasco E, et al. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features. Arthritis & rheumat. 2019 Jun;71(6):1011–1021.
   PubMed Web of Science ®Google Scholar
• Kim H, Gunter-Rahman F, McGrath JA, et al. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther. 2020 Apr 6;22(1):69. doi: 10.1186/s13075-020-02160-9
   PubMed Web of Science ®Google Scholar
• Castelo-Soccio L, Kim H, Gadina M, et al. Protein kinases: drug targets for immunological disorders. Nat Rev Immunol. 2023 May;15:1–20.
   Google Scholar
• Aeschlimann FA, Fremond ML, Duffy D, et al. A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain. 2018 Nov 1;141(11):e80. doi: 10.1093/brain/awy255
   PubMed Web of Science ®Google Scholar
• Agud-Dios M, Arroyo-Andres J, Rubio-Muniz C, et al. Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy. Dermatol Ther. 2022 Dec;35(12):e15960.
   PubMed Web of Science ®Google Scholar
• Ng PLP C, Mopur A, Goh DYT, et al. Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease. Int J Rheum Dis. 2022 Feb;25(2):228–231.
   PubMed Web of Science ®Google Scholar
• Ding Y, Huang B, Wang Y, et al. Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis. Ann Rheumatic Dis. 2021;80(4):543–545. doi: 10.1136/annrheumdis-2020-218582
   PubMed Web of Science ®Google Scholar
• Heinen A, Schnabel A, Bruck N, et al. Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis? Rheumatology (Oxford). 2021 Apr 6;60(4):e136–e138. doi: 10.1093/rheumatology/keaa657
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Celikel E, Gungorer V, et al. Cardiac involvement in a case of juvenile dermatomyositis with positive anti-melanoma differentiation associated protein 5 antibody. Int J Of Rheum Dis. 2023 Aug;26(8):1582–1585.
   PubMed Web of Science ®Google Scholar
• Kim H, Dill S, Brien M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheumatic Dis. 2021;80(3):406–408. doi: 10.1136/annrheumdis-2020-218690
   PubMed Web of Science ®Google Scholar
• Kostik MM, Raupov RK, Suspitsin EN, et al. The safety and efficacy of tofacitinib in 24 cases of pediatric rheumatic diseases: single centre experience. Front Pediatr. 2022;10:820586. doi: 10.3389/fped.2022.820586
   PubMed Web of Science ®Google Scholar
• Le Voyer T, Gitiaux C, Authier FJ, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology (Oxford). 2021 Dec 1;60(12):5801–5808. doi: 10.1093/rheumatology/keab116
   PubMed Web of Science ®Google Scholar
• Mastrolia MV, Orsini SI, Marrani E, et al. Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis. Clin Exp Rheumatol. 2023 Mar;41(2):402–403.
   PubMed Web of Science ®Google Scholar
• Min MS, Alsarheed A, Kassamali B, et al. Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers. J Am Acad Dermatol. 2022 Feb;86(2):423–425.
   PubMed Web of Science ®Google Scholar
• Papadopoulou C, Hong Y, Omoyinmi E, et al. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain. 2019 Mar 1;142(3):e8. doi: 10.1093/brain/awz005
   PubMed Web of Science ®Google Scholar
• Sabbagh S, Almeida de Jesus A, Hwang S, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019 Nov 1;142(11):e59. doi: 10.1093/brain/awz293
   PubMed Web of Science ®Google Scholar
• Sozeri B, Demir F. A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate. Rheumatology (Oxford). 2020 Aug 4;59(12):e140–e141. doi: 10.1093/rheumatology/keaa360
   PubMed Web of Science ®Google Scholar
• Wang Z, Zheng Q, Xuan W, et al. Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis. Front Pediatr. 2022;10:962585. doi: 10.3389/fped.2022.962585
   PubMed Web of Science ®Google Scholar
• Yu Z, Wang L, Quan M, et al. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Rheumatology (Oxford). 2021 Apr 6;60(4):1700–1707. doi: 10.1093/rheumatology/keaa558
   PubMed Web of Science ®Google Scholar
• Zhou Q, Weng R, Xia Y. Refractory juvenile dermatomyositis: Response to tofacitinib. Med Clin. 2022 Jan 21;158(2):95–96. doi: 10.1016/j.medcli.2021.03.022
   PubMed Web of Science ®Google Scholar
• Xue Y, Zhang J, Deng J, et al. Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients. Ann Rheum Dis. 2023 Jun 6;82(11):1499–1501. doi: 10.1136/ard-2023-223919
   PubMed Web of Science ®Google Scholar
• Rider LG, Aggarwal R, Pistorio A, et al. 2016 American College of Rheumatology/European League against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis & Rheumat. 2017 May;69(5):911–923.
   PubMed Web of Science ®Google Scholar
• Rider LG, Aggarwal R, Machado PM, et al. Update on outcome assessment in myositis. Nat Rev Rheumatol. 2018 May;14(5):303–318.
   PubMed Web of Science ®Google Scholar
• Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, manual muscle testing (MMT), health assessment questionnaire (Haq)/childhood health assessment questionnaire (C-HAQ), childhood myositis assessment Scale (CMAS), myositis disease activity assessment tool (MDAAT), disease activity score (DAS), short form 36 (SF-36), child health questionnaire (CHQ), physician global damage, myositis damage index (MDI), quantitative muscle testing (QMT), myositis functional Index-2 (FI-2), myositis activities profile (MAP), inclusion body myositis functional rating Scale (IBMFRS), cutaneous dermatomyositis disease area and severity index (CDASI), cutaneous assessment tool (CAT), dermatomyositis skin severity index (DSSI), skindex, and dermatology life quality index (DLQI). Arthritis Care Res (Hoboken). 2011 Nov;63(Suppl 11):S118–57.
   PubMed Web of Science ®Google Scholar
• Anyanwu CO, Fiorentino DF, Chung L, et al. Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015 Oct;173(4):969–74.
   PubMed Web of Science ®Google Scholar
• Lazarevic D, Pistorio A, Palmisani E, et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013 May;72(5):686–93.
   PubMed Web of Science ®Google Scholar
• Almeida B, Campanilho-Marques R, Arnold K, et al. Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated. Arthritis & rheumat. 2015 Sep;67(9):2495–502.
   PubMed Web of Science ®Google Scholar
• Tsaltskan V, Aldous A, Serafi S, et al. Long-term outcomes in Juvenile Myositis patients. Semin Arthritis Rheum. 2020 Jun 28;50(1):149–155. doi: 10.1016/j.semarthrit.2019.06.014
   PubMed Web of Science ®Google Scholar
• Kul Cinar O, Papadopoulou C, Pilkington CA. Treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2021 Feb 8;23(2):13. doi: 10.1007/s11926-020-00974-9
   PubMed Web of Science ®Google Scholar
• Pinotti CS, Cannon L, Dvergsten JA, et al. Calcinosis in juvenile dermatomyositis: Updates on pathogenesis and treatment. Front Med. 2023;10:1155839. doi: 10.3389/fmed.2023.1155839
   Web of Science ®Google Scholar
• Kobayashi I, Okura Y, Yamada M, et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 2011 Apr;158(4):675–7.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Takezaki S, Kobayashi I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford). 2015 May;54(5):784–91.
   PubMed Web of Science ®Google Scholar
• Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021;12:773352. doi: 10.3389/fimmu.2021.773352
   PubMed Web of Science ®Google Scholar
• Tansley SL, Li D, Betteridge ZE, et al. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology (Oxford). 2020 Aug 1;59(8):2109–2114. doi: 10.1093/rheumatology/keaa021
   PubMed Web of Science ®Google Scholar
• Kim H, Brooks KM, Tang CC, et al. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor Baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther. 2018 Aug;104(2):364–373.
   PubMed Web of Science ®Google Scholar
• Khandelwal P, Teusink-Cross A, Davies SM, et al. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2017 Jul;23(7):1122–1127.
   PubMed Web of Science ®Google Scholar
• Loh ML, Tasian SK, Rabin KR, et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children’s Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 Oct;62(10):1717–24.
   PubMed Web of Science ®Google Scholar
• Fremond ML, Rodero MP, Jeremiah N, et al. Efficacy of the janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016 Dec;138(6):1752–1755.
   PubMed Web of Science ®Google Scholar
• Balanescu AR, Citera G, Pascual-Ramos V, et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL surveillance trial. Ann Rheum Dis. 2022 Nov;81(11):1491–1503.
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316–326. doi: 10.1056/NEJMoa2109927
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3–18.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Harigai M, Genovese MC, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020 Oct;79(10):1290–1297.
   PubMed Web of Science ®Google Scholar
• Lussana F, Cattaneo M, Rambaldi A, et al. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018 Mar;93(3):339–347.
   PubMed Web of Science ®Google Scholar
• Bird P, Bensen W, El-Zorkany B, et al. Tofacitinib 5 mg twice daily in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs: a comprehensive review of phase 3 efficacy and safety. J Clin Rheumatol. 2019 Apr;25(3):115–126.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015 Feb;74(2):333–40.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Tanaka Y, et al. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key phase 2 studies. Int J Of Rheum Dis. 2016 Dec;19(12):1216–1225.
   PubMed Web of Science ®Google Scholar
• Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020 May 7;382(19):1800–1810. doi: 10.1056/NEJMoa1917635
   PubMed Web of Science ®Google Scholar
• Sanchez GAM, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018 Jul 2;128(7):3041–3052. doi: 10.1172/JCI98814
   PubMed Web of Science ®Google Scholar
• Diamantopoulos PT, Kalopisis K, Tsatsou A, et al. Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies. Eur J Haematol. 2022 May;108(5):359–368.
   PubMed Web of Science ®Google Scholar
• Yun J, Osehobo E, Lawson EC, et al. Tofacitinib-induced progressive multifocal leukoencephalopathy with immune reconstitution inflammatory syndrome. Clin Neurol Neurosur. 2022 Mar;214:107143.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Synoverska O, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021 Nov 27;398(10315):1984–1996. doi: 10.1016/S0140-6736(21)01255-1
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Quartier P, Okamoto N, et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023 Aug 12;402(10401):555–570. doi: 10.1016/S0140-6736(23)00921-2
   PubMed Web of Science ®Google Scholar
• Jagasia M, Perales MA, Schroeder MA, et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14;135(20):1739–1749. doi: 10.1182/blood.2020004823
   PubMed Web of Science ®Google Scholar
• Neelakantan S, Oemar B, Johnson K, et al. Safety, tolerability, and pharmacokinetics of PF-06823859, an anti-interferon beta monoclonal antibody: a randomized, phase I, single- and multiple-ascending-dose study. Clin Pharmacol Drug Dev. 2021 Mar;10(3):307–316.
   PubMed Web of Science ®Google Scholar